grant

Correlation of methylation profiles with cancer testis antigen expression and response to chemotherapy in non small cell lung cancer [ 2013 - 2014 ]

Also known as: NY-ESO-1 expression as an inducible chemosensitivity marker

Funded by National Health and Medical Research Council
Managed by La Trobe University
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/1056577]

Brief description Immunotherapy is a new concept treatment for lung cancer. Cancer testis antigen (CTA, eg NY-ESO-1) is an immunogenic molecule that was related with poor outcomes, but our recent studies have found that tumours that express NY-ESO-1 are more responsive to chemotherapy. We are also able to induce expression of NY-ESO-1 in cells that do not normally express it using demethylating agents. We aim to determine if we can increase the response to chemotherapy by using these drugs in combination.

Funding Amount $AUD 79,514.86

Funding Scheme Postgraduate Scholarships

Notes Medical/Dental Postgraduate Scholarship

Click to explore relationships graph
Help

Related Organisations

Subjects
Cancer Therapy (Excl. Chemotherapy and Radiation Therapy) | Medical and Health Sciences | Oncology and Carcinogenesis | chemotherapy | epigenetics | immunotherapy | lung cancer | oncology |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA
ACN 633 798 857